Oxford Cancer Biomarkers — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Oxford Cancer Biomarkers is a private, commercial-stage diagnostics company leveraging biomarker and AI technology to personalize cancer care, starting with colorectal cancer. Its lead commercial product, ToxNav®, predicts patient risk of severe toxicity from common chemotherapies (5-FU/capecitabine), while its prognostic test, OncoProg, uses AI and digital pathology to stratify relapse risk. Founded by academic oncologists, the company is expanding through U.S. and European partnerships and has a pipeline aimed at broadening its technology to other cancers.

OncologyColorectal Cancer

Technology Platform

Proprietary biomarker technologies integrating pharmacogenomics, digital pathology, and artificial intelligence (AI) to create clinical decision support tools for cancer diagnosis, prognosis, and treatment optimization.

Opportunities

The global push for personalized medicine and mandatory pre-treatment DPYD testing in some regions creates a significant tailwind for ToxNav® adoption.

Expanding its AI-driven prognostic platform (OncoProg) to other cancer types represents a major pipeline growth opportunity.

Strategic partnerships, like the one with Mira Precision Health for the U.S.

market, enable capital-efficient geographic expansion.

Risk Factors

Commercial success depends on securing favorable reimbursement from healthcare payers and displacing established testing practices.

The prognostic test market is competitive, requiring robust clinical validation to gain market share.

The company's U.S.

strategy is reliant on the execution capability of its partner, Mira Precision Health, creating dependency risk.

Competitive Landscape

OCB competes in the pharmacogenomic testing space against large central labs (e.g., Quest, LabCorp) and other specialty diagnostics firms offering DPYD testing. In the colorectal cancer prognostic segment, it faces established competitors like Exact Sciences' Oncotype DX Colon Recurrence Score test. Its differentiation lies in its academic founder pedigree, integrated AI/digital pathology approach, and a focused product suite for the colorectal cancer care pathway.

More companies in United Kingdom →